Linda Pan

2.1k total citations
23 papers, 1.1k citations indexed

About

Linda Pan is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Linda Pan has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 16 papers in Immunology and 5 papers in Oncology. Recurrent topics in Linda Pan's work include Immunotherapy and Immune Responses (16 papers), vaccines and immunoinformatics approaches (10 papers) and T-cell and B-cell Immunology (7 papers). Linda Pan is often cited by papers focused on Immunotherapy and Immune Responses (16 papers), vaccines and immunoinformatics approaches (10 papers) and T-cell and B-cell Immunology (7 papers). Linda Pan collaborates with scholars based in United States, Australia and Germany. Linda Pan's co-authors include Lloyd J. Old, Eric W. Hoffman, Gerd Ritter, Ralph Venhaus, Sacha Gnjatic, Achim A. Jungbluth, Anna C. Pavlick, Maha Ayyoub, Danila Valmori and Kunle Odunsi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Linda Pan

23 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Linda Pan United States 11 895 522 444 110 106 23 1.1k
Ralph Venhaus United States 14 555 0.6× 443 0.8× 302 0.7× 123 1.1× 84 0.8× 44 888
Drew C. Deniger United States 14 737 0.8× 874 1.7× 302 0.7× 44 0.4× 166 1.6× 18 1.2k
Wayne Aldrich United States 19 590 0.7× 419 0.8× 501 1.1× 42 0.4× 262 2.5× 46 1.1k
Gabriele Pecher Germany 17 810 0.9× 553 1.1× 591 1.3× 62 0.6× 114 1.1× 45 1.2k
Barry Kobrin United States 10 441 0.5× 442 0.8× 278 0.6× 104 0.9× 74 0.7× 18 816
C H Delgado United States 8 1.5k 1.6× 840 1.6× 755 1.7× 70 0.6× 251 2.4× 8 1.9k
Jan Diekmann Germany 10 1.4k 1.6× 1.1k 2.1× 717 1.6× 43 0.4× 131 1.2× 12 1.8k
Jacob Ricca United States 8 392 0.4× 583 1.1× 297 0.7× 64 0.6× 340 3.2× 12 933
Cleo Goyvaerts Belgium 23 821 0.9× 648 1.2× 646 1.5× 37 0.3× 175 1.7× 48 1.4k
Niels van de Roemer Germany 3 1.3k 1.4× 1.0k 2.0× 597 1.3× 39 0.4× 103 1.0× 7 1.5k

Countries citing papers authored by Linda Pan

Since Specialization
Citations

This map shows the geographic impact of Linda Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda Pan more than expected).

Fields of papers citing papers by Linda Pan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda Pan. The network helps show where Linda Pan may publish in the future.

Co-authorship network of co-authors of Linda Pan

This figure shows the co-authorship network connecting the top 25 collaborators of Linda Pan. A scholar is included among the top collaborators of Linda Pan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda Pan. Linda Pan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pan, Linda, Evelyn Powell, Konstantin Latychev, et al.. (2021). RAPID POSTGLACIAL REBOUND AMPLIFIES GLOBAL SEA-LEVEL RISE FOLLOWING WEST ANTARCTIC ICE SHEET COLLAPSE. Abstracts with programs - Geological Society of America. 1 indexed citations
2.
Reardon, David A., Jörg Dietrich, Thomas Kaley, et al.. (2015). Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).. Journal of Clinical Oncology. 33(15_suppl). TPS2077–TPS2077. 3 indexed citations
3.
Ott, Patrick A., Margaret K. Callahan, Kunle Odunsi, et al.. (2015). A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). TPS3099–TPS3099. 3 indexed citations
4.
Chen, Ji‐Li, Andrea Tarlton, Sacha Gnjatic, et al.. (2014). NY‐ESO ‐1 specific antibody and cellular responses in melanoma patients primed with NY‐ESO ‐1 protein in ISCOMATRIX and boosted with recombinant NY‐ESO ‐1 fowlpox virus. International Journal of Cancer. 136(6). E590–601. 40 indexed citations
5.
6.
Sabado, Rachel Lubong, Anna C. Pavlick, Sacha Gnjatic, et al.. (2014). Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.. Journal of Clinical Oncology. 32(15_suppl). TPS9119–TPS9119. 3 indexed citations
7.
Callahan, Margaret K., Patrick A. Ott, Kunle Odunsi, et al.. (2014). A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). TPS3120–TPS3120. 22 indexed citations
8.
Sabado, Rachel Lubong, Anna C. Pavlick, Sacha Gnjatic, et al.. (2014). Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.. Journal of Clinical Oncology. 32(15_suppl). 9086–9086. 2 indexed citations
9.
Tsuji, Takemasa, Paul Sabbatini, Achim A. Jungbluth, et al.. (2013). Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial. Cancer Immunology Research. 1(5). 340–350. 52 indexed citations
10.
11.
Ott, Patrick A., Richard D. Carvajal, Neeta Pandit‐Taskar, et al.. (2012). Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Investigational New Drugs. 31(2). 425–434. 121 indexed citations
12.
Sabado, Rachel Lubong, Anna C. Pavlick, Sacha Gnjatic, et al.. (2012). Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.. Journal of Clinical Oncology. 30(15_suppl). 2589–2589. 5 indexed citations
13.
Ready, Neal, Lee M. Krug, M. Catherine Pietanza, et al.. (2012). Phase II study of ADI-PEG 20 in patients with relapsed sensitive or refractory small cell lung cancer.. Journal of Clinical Oncology. 30(15_suppl). e17558–e17558. 2 indexed citations
14.
Kakimi, Kazuhiro, Midori Isobe, Akiko Uenaka, et al.. (2011). A phase I study of vaccination with NY‐ESO‐1f peptide mixed with Picibanil OK‐432 and Montanide ISA‐51 in patients with cancers expressing the NY‐ESO‐1 antigen. International Journal of Cancer. 129(12). 2836–2846. 66 indexed citations
15.
Nicholaou, Theo, Weisan Chen, Ian D. Davis, et al.. (2011). Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™. Cancer Immunology Immunotherapy. 60(11). 1625–1637. 35 indexed citations
16.
Nicholaou, Theo, Lisa M. Ebert, Ian D. Davis, et al.. (2009). Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma. Clinical Cancer Research. 15(6). 2166–2173. 100 indexed citations
17.
Valmori, Danila, Naira E. Souleimanian, Valeria Tosello, et al.. (2007). Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proceedings of the National Academy of Sciences. 104(21). 8947–8952. 243 indexed citations
18.
Bender, Armin, Julia Karbach, Antje Neumann, et al.. (2007). LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.. PubMed. 7. 16–16. 47 indexed citations
19.
Jäger, Elke, Julia Karbach, Sacha Gnjatic, et al.. (2006). Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proceedings of the National Academy of Sciences. 103(39). 14453–14458. 172 indexed citations
20.
Rana, Brinda K., Linda Pan, & Paul A. Insel. (2001). Use of an in Silico Approach to Define the Gene Structure of Eukaryotic Adenylyl Cyclases. Biochemical and Biophysical Research Communications. 285(1). 152–157. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ralph Venhaus Breakdown of academic impact, for papers by Drew C. Deniger Breakdown of academic impact, for papers by Wayne Aldrich Breakdown of academic impact, for papers by Gabriele Pecher Breakdown of academic impact, for papers by Barry Kobrin Breakdown of academic impact, for papers by C H Delgado Breakdown of academic impact, for papers by Jan Diekmann Breakdown of academic impact, for papers by Jacob Ricca Breakdown of academic impact, for papers by Cleo Goyvaerts Breakdown of academic impact, for papers by Niels van de Roemer
Rankless by CCL
2026